| Press Release |
DBV Technologies Reports
Full Year 2016 Financial Results
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its full year 2016 results. Audit procedures on the Company`s 2016 consolidated financial statements were completed by the Company`s statutory auditors. The issuance of the audit report is pending.
Full year 2016 results
Selected financial information (IFRS consolidated financial statements)
| In million euros | 2015 | 2016 |
| Operating income | 6.2 | 9.1 |
| Research and development expenses | (34.2) | (78.8) |
| Sales and marketing expenses | (0.5) | (11.3) |
| General and administrative expenses | (16.9) | (35.0) |
| Operating profit (loss) | (45.5) | (116.0) |
| Net profit (loss) | (44.7) | (114.5) |
| Earnings (loss) per share (in € per share) | (2.08) | (4.68) |
| Net cash flow used in operating activities | (26.8) | (59.5) |
| Net cash flow provided by financing activities | 241.0 | 1.7 |
| Net increase / (decrease) in cash and cash equivalents | 208.9 | (66.2) |
| Cash and cash equivalents at closing (December 31st) | 323.4 | 256.5 |
Operating income for the full year of 2016 was €9.1 million, an increase of 47% compared to 2015. In 2016, income was mainly generated by the Company`s research tax credit (Crédit Impôt Recherche) and by income recognized under the May 2016 collaboration agreement with Nestlé Health Science, and more marginally, by subsidies received for research projects conducted by the Company.
Research and development expenses in 2016 were €78.8 million, an increase of 130% compared to 2015. This increase in expenditures resulted from costs associated with PEPITES, PEOPLE and REALISE Phase III trials of Viaskin Peanut, the ongoing MILES Phase I/II trial of Viaskin Milk, as well as a substantial increase in research and development personnel to support the Company`s increasing number of active development programs.
General and administrative expenses increased to €35.0 million in 2016 from €16.9 million in 2015, an increase of 108%. This increase was primarily due to increased general and administrative headcount and professional fees for auditing, tax and legal services to support the Company`s continued growth and expanding operations.
Sales and marketing expenses were €11.3 million in 2016 compared to €0.5 million for the same period in 2015. These expenses included payroll for U.S. employees, as well as expenses related to the launch and commercialization of Viaskin Peanut in North America, if the appropriate regulatory approvals are received.
The Company`s net loss for the full year 2016 was €(114.5) million compared to €(44.7) million in 2015. The loss per share (based on the weighted average number of shares outstanding over the period) was €(4.68) and €(2.08) for 2016 and 2015, respectively.